Tagged with EG

Pharma Rafael Suarez, general manager of Ferring in Mexico, explains how the Swiss biopharmaceutical company is adapting to the recent dynamics affecting both the Mexican public and private sectors. He outlines his approach to further consolidate the Mexican affiliate, increase Ferring’s clinical research investments and manufacturing presence in Mexico. When Pharmaceutical…

Pharma Dr. Teresa Corona Vázquez, the general director of one of the leading neuroscience institutions in Latin America, details their most important research partnerships and achievements, notably with regards to neurodegenerative diseases, and her expectations of fostering a heightened research-based relationship with the pharmaceutical industry. What have been some of the…

Pharma Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries…

Women's H|alth “The right people at the right time at the right place with the right products” – The general manager for Exeltis Czech Republic & Slovakia reviews her strategy and key elements that led to 35 percent growth in her first two years at the Czech affiliate. Furthermore, she elaborates how…

Pharma The Head of Sanofi-Genzyme’s Czech & Slovak affiliate points out that his affiliate generates a third of the regional turnover for the group as rules and regulations in his market resemble a paradise in regional comparison. The high commitment to patients is highlighted as a fundamental reason for this success!…

Pharma Building on the continuous improvements of the Federal Commission for the Protection Against Sanitary Risk (Cofepris) over the last few years, its recently-appointed Federal Commissioner Julio Sánchez y Tépoz reveals his strategy to further strengthen and develop the Commission’s processes and international leadership, and foster a more transparent, technical, efficient…

Pharma The following chart illustrates the various bottlenecks restraining the development of France’s pharmaceutical industry, including lack of investment, fewer new molecules than other European countries, disappointing performance in biological drugs, and long waiting times for drug approval. Click here to read more articles and interviews from France, and to download the…

Pharma Matthieu Brand, who has been heading the French affiliate of World Courier, AmerisourceBergen for 2.5 years now, shares with great passion the bright future lying ahead of the company in France, their “a la carte” logistics service offering in the fields of clinical trials and R&D, as well the ambitions…

Pharma Eisai’s Czech Republic’s Operations Manager discusses the role Eisai plays in the country, the transparency of the pharma industry in the region, and his aspirations for the future. What does the Czech market have to offer Eisai compared to its neighboring countries? The Czech Republic is one of the most…

Pharma Socorro España Lomelí, executive director of Mexico’s National Association of Drug Manufacturers (ANAFAM), details her strategic priorities with regards to the promotion of the industry’s export strategy, the implementation of world-class manufacturing norms, the development of biosimilars and API manufacturing, as well as recognizing the pharmaceutical sector as a strategic…

Pharma Dr. Lívia Ilku, director of Hungary’s main domestic pharmaceutical manufacturers’ association (MAGYOSZ), describes the current priorities of its member companies and the key factors for success in Hungary; specifically innovation and complying with regulatory standards. Given its more than 100-year legacy in the country, how has the pharmaceutical industry supported…

Pharma The country manager of Pfizer Czech Republic reviews the advantages of Pfizer’s highly differentiated pipeline and points out how it will impact the success of the Czech affiliate in the future. Furthermore, he describes how he plans to position Pfizer as partner to the relevant stakeholders in order to utilize…